Against pediatric B-ALL cells which express low levels of CD20, a CD19 targeting NKCE which ligates CD16 in combination with either NKp46 or NKp30 showed potent activation of NK cells against primary B-ALL cells and could overcome inhibitory HLA-mediated interactions [96]. The gene discussed is NCR3; the disease is acute lymphoblastic leukemia.